×

Viral Trap Technology, Cornerstone US Patent and Specifications for Sale from ICAP Patent Brokerage

ICAP Patent Brokerage

New York, Feb. 18, 2014 (GLOBE NEWSWIRE) -- (http://www.myprgenie.com) -- ICAP Patent Brokerage announces for sale a novel means of enabling a host's own cells to collect, attach to, and eliminate harmful viruses, alleviating disease-causing infections and conditions, from inventor Lawrence F. Glaser. An embodiment of the invention is demonstrated as a mature red blood cell capable of attaching to and absorbing HIV particles. The teachings of the patent and specifications allow for customization of cells taken from hosts, thus assuring the cells returned will be compatible with the host, while targeting biological targets to which the cells would normally have no attraction.

"This invention has potential for use against all pathogens in mammalian hosts, and against cancer as well. The technique uses highly conserved proteins compatible with the host, so no side effects are anticipated. Also, the drugs prescribed for a given condition may be continued; there will be no adverse interaction, and the drug dosages may potentially be reduced, saving money, slowing viral drift (mutation) and reducing the side effects associated with the drugs. Recent work has shown great promise in fighting cancer utilizing related techniques," says Dean Becker, CEO of ICAP Patent Brokerage.

Key Characteristics & Benefits

Viruses have a natural affinity and attraction to human cells, such as HIV to the sensitive immune system cells. These new "viral trap" cells are made from a host's own cells (e.g., red blood cells), so the billions of different endogenous proteins on the surface of the cells will be instantly compatible with the host. The cells attract HIV particles, then trick the virus into thinking it has reached an immune system cell. The virus covalently attaches to the red blood cell and enters the cell. A virus particle can only enter one cell, and the chemistry in the red blood cell is wrong for the virus, so the virus is instantly and permanently disabled. Finberg, Turner, and others at Yale University successfully used the technique to suppress lethal mouse virus (coxxackie virus) in controlled studies with otherwise healthy mice and no side effects were noted. These methods are well known to those of skill in the art, as is the ability to retarget these modified cells to another biological target, based on the type of cell originally selected and the coreceptors added. One can use any logical cell taken from a host to target any pathogen or biological target which may be found within the host.

To learn more about the assets available for sale in this portfolio:

Contact Dean Becker of ICAP Patent Brokerage at (561) 573-0405 or via email at Dean.Becker@us.icap.com.

Follow us on Twitter (@ICAP_IP) and join our LinkedIn group.

About ICAP Patent Brokerage

ICAP Patent Brokerage is the world's largest intellectual property brokerage and patent auction firm, leveraging the talents of experienced intellectual property monetization professionals to match buyers and sellers for the sale of patents and other intellectual property assets. With multiple transaction platforms and unparalleled industry knowledge and experience, ICAP Patent Brokerage is the market leader in the transaction of intellectual property.

CONTACT: Sarah Saites, sarah.saites@us.icap.com, 312-327-4437

Source:ICAP Patent Brokerage LLC